Zymeworks Inc. ZYME

What this company does

Zymeworks manages a portfolio of licensed healthcare assets and develops a pipeline of multifunctional biotherapeutics for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors developed using the company's Azymetric platform, has received regulatory approval for the treatment of HER2-positive biliary tract cancer in the United States, China, Europe and Canada. The company has entered into collaboration and license agreements with BeOne Medicines Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each partner exclusive rights to develop and commercialize zanidatamab in different territories. Pasritamig, a bispecific T cell engager targeting human kallikrein 2, was engineered using Zymeworks' Azymetric platform. As of December 31, 2025, the company had 264 full-time employees, 184 of whom were based in Canada, 66 in the United States, and 14 in Singapore, Ireland and the United Kingdom. Effective October 13, 2022, the company became a Delaware corporation, and Zymeworks Inc. was incorporated under the laws of the State of Delaware in June 2022, with principal executive offices located at 108 Patriot Drive, Suite A, Middletown, Delaware. Its predecessor, now named Zymeworks BC Inc., was originally incorporated on September 8, 2003 under the Canada Business Corporations Act under the name "Zymeworks Inc."

Written from the business description in Zymeworks Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.